Islet organoid as a promising model for diabetes

Zhang, Xiaofei; Ma, Zhuo; Song, Eli; Xu, Tao

doi:10.1007/s13238-021-00831-0

Cited by 37 publications

(30 citation statements)

References 158 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The advances in this field were recently reviewed by Sharma et al [164]. In diabetes research, the current trend is moving toward developing islet organoids, which can provide large amounts of functional islets and therefore be used in underpinning disease mechanisms in vitro [165,166].…”

Section: Pluripotent Stem Cells For Mody Disease Modelling and Drug Researchmentioning

confidence: 99%

Maturity Onset Diabetes of the Young—New Approaches for Disease Modelling

Skoczek

Dulak

Kachamakova‐Trojanowska

2021

IJMS

View full text Add to dashboard Cite

Maturity-onset diabetes of the young (MODY) is a genetically heterogeneous group of monogenic endocrine disorders that is characterised by autosomal dominant inheritance and pancreatic β-cell dysfunction. These patients are commonly misdiagnosed with type 1 or type 2 diabetes, as the clinical symptoms largely overlap. Even though several biomarkers have been tested none of which could be used as single clinical discriminator. The correct diagnosis for individuals with MODY is of utmost importance, as the applied treatment depends on the gene mutation or is subtype-specific. Moreover, in patients with HNF1A-MODY, additional clinical monitoring can be included due to the high incidence of vascular complications observed in these patients. Finally, stratification of MODY patients will enable better and newer treatment options for MODY patients, once the disease pathology for each patient group is better understood. In the current review the clinical characteristics and the known disease-related abnormalities of the most common MODY subtypes are discussed, together with the up-to-date applied diagnostic criteria and treatment options. Additionally, the usage of pluripotent stem cells together with CRISPR/Cas9 gene editing for disease modelling with the possibility to reveal new pathophysiological mechanisms in MODY is discussed.

show abstract

Section: Pluripotent Stem Cells For Mody Disease Modelling and Drug Researchmentioning

confidence: 99%

Maturity Onset Diabetes of the Young—New Approaches for Disease Modelling

Skoczek

Dulak

Kachamakova‐Trojanowska

2021

IJMS

View full text Add to dashboard Cite

show abstract

“…Despite there are still some imperfections in islet organoid technology, islet organoid systems have already been proven to promote the studies of human islet, especially in the field of human islet development, diabetic disease model and islet transplantation 12 , 181 . Nearly two decades have passed since the first success of the Edmonton protocol, the cadaveric islets have not been the only resource for transplantation.…”

Section: Challenges and Perspectivesmentioning

confidence: 99%

“…Over the past decade, the islet organoid has attracted increasing attention as a promising model for diabetes to reveal the mechanism of islet-related diseases and an excellent platform to test the potency and toxicity of drugs. For instance, islet organoid can fill the blank of our knowledge about human pancreatic development between relevant early (<8 weeks gestation) and later gestational-aged human pancreatic tissue (>22 weeks gestation), and it is expected to be a new islet resource of transplantation in diabetes therapy 12 - 15 . Many reviews have discussed the potential and significance of islet organoids, but none of them has given us a comprehensive summary of “how to make human pancreatic islet organoids”.…”

Section: Introductionmentioning

confidence: 99%

Making human pancreatic islet organoids: Progresses on the cell origins, biomaterials and three-dimensional technologies

Jiang¹,

Shen²,

Liu³

et al. 2022

Theranostics

View full text Add to dashboard Cite

Diabetes is one of the most socially challenging health concerns. Even though islet transplantation has shown promise for insulin-dependent diabetes, there is still no effective method for curing diabetes due to the severe shortage of transplantable donors. In recent years, organoid technology has attracted lots of attention as organoid can mirror the human organ in vivo to the maximum extent in vitro, thus bridging the gap between cellular- and tissue/organ-level biological models. Concurrently, human pancreatic islet organoids are expected to be a considerable source of islet transplantation. To construct human islet-like organoids, the seeding cells, biomaterials and three-dimensional structure are three key elements. Herein, this review summarizes current progresses about the cell origins, biomaterials and advanced technology being applied to make human islet organoids, and discusses the advantages, shortcomings, and future challenges of them as well. We hope this review can offer a cross-disciplinary perspective to build human islet organoids and provide insights for tissue engineering and regenerative medicine.

show abstract

“…Beta-like cells differentiated from iPSCs of Wolfram syndrome patients showed decreased insulin content and increased activity of molecules related to endoplasmic reticulum stress, suggesting that beta cell failure is caused by WFS1 deficiency [122]. For a more detailed overview of disease modelling with organoids, we refer the reader to an article by Clevers, who published a comprehensive review of "Disease modelling with organoids" [123], as well as a recent paper by Zhang et al that specifically focuses on the review of organoids as "Promising in vitro models for diabetes" [124].…”

Section: Organoidsmentioning

confidence: 99%

In Vitro Disease Models of the Endocrine Pancreas

et al. 2021

View full text Add to dashboard Cite

The ethical constraints and shortcomings of animal models, combined with the demand to study disease pathogenesis under controlled conditions, are giving rise to a new field at the interface of tissue engineering and pathophysiology, which focuses on the development of in vitro models of disease. In vitro models are defined as synthetic experimental systems that contain living human cells and mimic tissue- and organ-level physiology in vitro by taking advantage of recent advances in tissue engineering and microfabrication. This review provides an overview of in vitro models and focuses specifically on in vitro disease models of the endocrine pancreas and diabetes. First, we briefly review the anatomy, physiology, and pathophysiology of the human pancreas, with an emphasis on islets of Langerhans and beta cell dysfunction. We then discuss different types of in vitro models and fundamental elements that should be considered when developing an in vitro disease model. Finally, we review the current state and breakthroughs in the field of pancreatic in vitro models and conclude with some challenges that need to be addressed in the future development of in vitro models.

show abstract

Islet organoid as a promising model for diabetes

Cited by 37 publications

References 158 publications

Maturity Onset Diabetes of the Young—New Approaches for Disease Modelling

Maturity Onset Diabetes of the Young—New Approaches for Disease Modelling

Making human pancreatic islet organoids: Progresses on the cell origins, biomaterials and three-dimensional technologies

In Vitro Disease Models of the Endocrine Pancreas

Contact Info

Product

Resources

About